Ginkgo Bioworks shares jump 10.22% intraday after expanding service offerings and enhancing R&D efficiency with Autonomous Lab and AI/ML platform.

Ginkgo Bioworks surged 10.22% intraday as the company disclosed in its 2025 annual report that its two core businesses are providing bio R&D tools and services for cell engineering and offering biosecurity solutions for government and commercial clients through biological threat monitoring and protection services. The report also noted that in 2024, the company expanded its service offerings to include tools allowing clients to conduct certain bio R&D independently, while leveraging its Autonomous Lab and AI/ML platform to enhance success rates, speed, and cost efficiency in R&D.